Letter to the EditorAntipsychotics, mortality and schizophrenia: What are the facts?
References (14)
- et al.
World Psychiatry Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia
Schizophr. Res.
(2008) - et al.
Schizophrenia, “just the facts” 4. Clinical features and conceptualization
Schizophr. Res.
(2009) - et al.
Schizophrenia, “just the facts” 5. Treatment and prevention
Schizophr. Res.
(2010) - et al.
11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study)
Lancet
(2009) - et al.
Cochrane Schizophrenia Group publications
- et al.
The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements
Schizophr. Bull.
(2010) - et al.
Schizophrenia Patient Outcomes Research Team (PORT). The 2009 schizophrenia PORT psychosocial treatment recommendations and summary statements
Schizophr. Bull.
(2010)
There are more references available in the full text version of this article.
Cited by (2)
Second-generation antipsychotic drugs and short-term mortality: a systematic review and meta-analysis of placebo-controlled randomised controlled trials
2018, The Lancet PsychiatryCitation Excerpt :Conversely, other observational studies have reported increased mortality associated with antipsychotic treatment.16–19 Synthesis and interpretation of these results is difficult and has led to intense discussion6,20–22 because of the specific methodological issues associated with these studies and also because confounding can never be ruled out completely in observational data. Randomised controlled trials offer the best source of evidence for estimating treatment effects, but single trials in this area are clearly underpowered because of the rarity of the mortality outcome.
Copyright © 2011 Elsevier B.V. All rights reserved.